US › Healthcare

Rigel Pharmaceuticals Inc (RIGL)

US · Healthcare · Biotechnology

$38.70+3.39%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$58.8M
Revenue YoY
+10.3%
Net profit
$8.7M
Profit YoY
-24.4%
EPS
$0.44
EPS estimate
$0.87
Net margin
14.7%

EPS came in at 0.44 against a street estimate of 0.87 — a miss of 49.4%.

Key statistics

Market cap
$681.1M
P/E
1.9
Forward P/E
8.2
P/B
1.70
Book value
$21.64
EPS (TTM)
$19.29
52-week high
$52.24
52-week low
$21.87
50-day MA
$35.64
200-day MA
$34.97
Beta
1.13

Analyst view

Analysts rate Rigel Pharmaceuticals Inc a buy (2 buy, 4 hold, 0 sell out of 6) with an average price target of $55.20.

Shareholding

Insiders
3.39%
Institutions
93.78%

Largest institutional holders

FundStake
BlackRock Inc9.56%
Armistice Capital, LLC6.92%
State Street Corp6.05%
Vanguard Capital Management, LLC4.13%
Acadian Asset Management LLC3.60%
LSV Asset Management3.25%
Marshall Wace Asset Management Ltd3.23%
American Century Companies Inc2.94%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Rigel Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.